This economic analysis found that alogliptin 25 mg strategy is likely to be more cost-effective in the Chinese healthcare system, as an alternative compared with linagliptin 5 mg, saxagliptin 5 mg, sitagliptin 100 mg, and vildagliptin 50 mg strategies for T2DM patients treated with DPP-4 inhibitors after failure of metformin treatment. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.